Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 181 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

 		Moderate to Severe Psoriatic Arthritis Phase2 United States NCT07801495

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)

 		Uncomplicated Plasmodium Falciparum Malaria Phase2 Burkina Faso
Côte d’Ivoire
Rwanda 		NCT07811908

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

 		Chronic Pruritus of Unknown Origin Phase3 United States NCT07811869

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

 		Chronic Pruritus of Unknown Origin Phase3 Argentina
Canada
Japan
South Korea
United States
View all
 NCT07700056

A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors

 		Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer Phase1 Australia
Japan 		NCT07801508

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

 		Sjögren's Disease Phase2 Australia
Canada
China
Israel
United States
View all
 NCT07737743

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

 		IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy Phase3 United States NCT07768371

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

 		Cutaneous Lichen Planus Phase2 Australia
Canada
China
United States
View all
 NCT07775924

A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment

 		Primary Immune Thrombocytopenia United States NCT07786077

A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

 		Multiple Sclerosis United States NCT07779460